Adiposity in Juvenile Psoriatic Arthritis

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.

From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.